Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Oct 2017 Planned initiation date changed from 20 Oct 2017 to 23 Oct 2017.
- 14 Oct 2017 Planned initiation date changed from 18 Oct 2017 to 20 Oct 2017.
- 09 Oct 2017 Planned initiation date changed from 3 Oct 2017 to 18 Oct 2017.